What is holding you back in the Human Microbiome Therapeutics Business?
Microbiome therapeutics have emerged as a novel therapeutic strategy, whereby living microbial cells or their components and metabolites are exploited to treat various diseases. Faecal microbial transplants (FMTs) have proved their success in treating recurring Clostridium difficile infections (CDI) for a long time. The potential of microbial therapeutics to address unmet medical needs has, therefore, been attracting many small- and big-players in this area. Still many human microbiome therapeutics companies are unable to make a move and grab this opportunity. In this report we have closely analysed human microbiome therapeutics market to find out a successful way out to grow in this tough crisis too. Buy our report to explore the goldmine areas in the global human microbiome therapeutics market.
Our 490+ page report provides 377 tables, 375 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing human microbiome therapeutics market. Buy our report to see how to exploit these opportunities in the global market.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Porter’s Five Forces Analysis, product profiles and commercial developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.
To access the data contained in this document please email contactus@visiongain.com
Discover sales predictions for the global human microbiome therapeutics market and submarkets
Along with revenue prediction for the overall world market, there are 5 segmentations of the human microbiome therapeutics market, with forecasts for 3 technologies, 6 Therapeutic Area, 3 Types, 4 Products each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.
Leading companies and the potential for market growth
As per Visiongain analysis, global human microbiome therapeutics market is estimated to be valued at US$xx million in 2020 and is projected to reach at a market value of US$xx million by 2031. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
What all Segments Are Covered in the Report?
Global Human Microbiome Therapeutics Market by Technology (COVID-19 Impact Recovery Analysis Covered)
• Genomics
• Proteomics
• Metabolomics
Global Human Microbiome Therapeutics Market by Therapeutic Area (COVID-19 Impact Recovery Analysis Covered)
• Neurological Disorders
• Dermatological Indications
• Cancers
• Metabolic Disorders
• Gastrointenstinal Disorders
• Other Therapeutic Areas
Global Human Microbiome Therapeutics Market by Type (COVID-19 Impact Recovery Analysis Covered)
• Fecal Microbiota Transplantation (FMT)
• Microbiome Drugs
• Microbiome Rebuilding
• Microbiome Preserving
Global Human Microbiome Therapeutics Market by Product (COVID-19 Impact Recovery Analysis Covered)
• Probiotics & Prebiotics
• Medical Food
• Diagnostic Tests
• Other Product
Global Human Microbiome Therapeutics Market by Region (COVID-19 Impact Recovery Analysis Covered)
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East
• Africa
Need industry data? Please contact us today.
Which Key Players Are Leading the Global Market and how much share do they Hold?
The global market for human microbiome therapeutics is ascending and has made significant gains in therapeutic treatments. The players in the human microbiome therapeutics market are striving to tap the opportunities that this market offers. Companies are trying to explore the available prospects by adopting various strategies such as:
• Mergers and acquisitions.
• Product launches.
• Collaborations and partnerships.
Product approval is a major milestone facing all key competitors in the human microbiome therapeutics market. Several strategies were implemented by key market players between 2015 and Dec 2020. There are over 200 microbiome companies involved in different aspects of microbiome therapeutics, including drugs, diagnostics, biomarkers, services, analyses and others.
How the Human Microbiome Therapeutics Market report helps you? Buy this report to find answers for below questions and how can help you to stay updated
• What is the current size of the overall global human human microbiome therapeutics market? How much will this market be worth from 2021 to 2031?
• How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
• Who are the leading companies and what are their activities, results, developments and prospects?
• What are some of the most prominent human human microbiome therapeutics currently in development?
• What are the main trends that will affect the world human microbiome therapeutics market between 2021 and 2031?
• What are the main strengths, weaknesses, opportunities and threats for the market?
• What are the social, technological, economic and political influences that will shape that industry over the next ten years?
• How will the global human microbiome therapeutics market evolve over the forecasted period, 2021 to 2031?
• How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2021 to 2031?
• Which therapies can succeed and what revenues could they generate to 2031?
• What will be the main commercial drivers for the market from 2021 to 2031?
• How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?
• How will that industry evolve between 2021 and 2031, especially in R&D?
Top 20 Leading Players Profiled in the Report
• AbbVie Inc. (AbbVie)
• Bristol-Myers Squibb
• Dow Inc Chemical
• Takeda Pharmaceutical Company Limited
• Johnson & Johnson
• DuPont de Nemours, Inc.
• Merck & Co. Inc
• Pfizer Inc.
• Vertex Pharmaceuticals
• Evelo Biosciences, Inc.
• Kaleido Biosciences, Inc.
• Seres Therapeutics, Inc.
• PureTech Health PLC
• Nestle S.A.
• Mayo Clinic
• MaaT Pharma SA
• 4D pharma plc (4D)
• Assembly Biosciences, Inc
• F. Hoffmann-La Roche Ltd
• Vedanta Biosciences
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the precision cancer diagnostic tests Market and leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Human Microbiome Therapeutics Market Report 2021-2031: Forecasts by Technology (Genomics, Proteomics, Metabolomics), by Therapeutic Area (Neurological Disorders, Dermatological Indications, Cancers, Metabolic Disorders, Gastrointestinal Disorders, Other Therapeutic Areas), by Type (Faecal Microbiota Transplantation (FMT), Microbiome Drugs, Microbiome Rebuilding, Microbiome Preserving), by Product (Probiotics & Prebiotics, Medical Food, Diagnostic Tests, Other Product) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Human Microbiome Therapeutics Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1 Report Overview
1.1 Global Human Microbiome Therapeutics Market Overview
1.2 Study Goals and Objectives
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.1 Key Questions Answered by This Analytical Report Include:
1.2 Who is This Report For?
1.3 Methodology
1.4.1 Primary Research
1.4.2 Secondary Research
1.4.3 Data Sources
1.4 Market Evaluation & Forecasting Methodology
1.5 COIVD-19 Impact Recovery Pattern Analysis
1.4.4 V-Shaped Recovery
1.4.5 U-Shaped Recovery
1.4.6 W-Shaped Recovery
1.4.7 L-Shaped Recovery
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain
2 Executive Summary
2.1 Key Take Away
3 Human Microbiome Therapeutics Products and Technology Overview
3.1 Introduction to Human Microbiome Therapeutics Products
3.1.1 The Human Microbiome
3.1.2 Gut Microbiome
3.1.3 Oral Microbiome
3.1.4 Skin Microbiome
3.2 Microbiome and Human Health and Disease
3.3 Essential Functions of Human Microbiome
3.4 Technologies Aiding Microbiome Research
3.5 Culturing and Cultivation
3.5.1 Animal Models
3.5.2 Gnotobiotic Animal Models
3.5.3 Engineered Systems
3.5.4 Organoid Cultures
3.5.5 Bioreactors
3.5.6 Microbiome Assaying
3.5.7 Direct Observation
3.5.8 Data Analysis
3.6 Microbiome Therapeutics Disease Areas
3.7 Regulatory Landscape for Microbiome Therapeutics
3.8 Microbiome Research Projects
4 Development of Microbiome Therapeutics
4.1 Additive Microbiome Therapy
4.2 Live Biotherapeutic Products (LBPs)
4.3 Modulatory Microbiome Therapy
4.3.1 Small Molecule Postbiotics
4.3.2 Prebiotics
4.4 Subtractive Microbiome Therapeutics
4.5 Antimicrobial Therapy
4.6 Phage Therapy
5 Market Dynamics
5.1 Overview
5.2 SWOT Analysis
5.3 Drivers of Microbiome Therapeutics Market
5.3.1 High Unmet Medical Need
5.3.2 Growing Understanding of the Microbiome
5.3.3 Positive Investment Environment
5.3.4 Strong Pipeline
5.3.5 Acceptance from Regulatory Authorities
5.4 Challenges for Microbiome Therapeutics Market
5.4.1 Lack of Regulatory Guidance
5.4.2 Product Characterization and Manufacturing Challenges
5.4.3 Hurdles in Preclinical and Clinical Research
5.4.4 Need for Skilled Labor
5.4.5 Emerging Markets
5.4.6 Development of Better Diagnostic Methods
5.4.7 Acquisitions and Partnerships
5.5 Threats to the Microbiome Therapeutics Market
5.5.1 New Government Regulations
5.5.2 Stiff Competition in the Global Market
5.5.3 COVID-19 Pandemic
6 Global Human Microbiome Therapeutics Market
6.1 Global Market Overview
6.2 Global Market Outlook in terms of Value (COVID-19 Impact Recovery Analysis)
6.3 Global Market Outlook by Region (COVID-19 Impact Recovery Analysis)
6.4 Global Market Outlook by Technology
6.4.1 Human Microbiome Therapeutics Technology Overview
6.4.2 Global Human Microbiome Therapeutics Market by Technology (Pre-COVID-19 Analysis)
6.4.3 Global Human Microbiome Therapeutics Market by Technology (Post-COVID-19 Impact Recovery Analysis)
6.5 Global Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
6.6 Global Market Outlook by Type
6.6.1 Fecal Microbiota Transplants (FMTs)
6.6.2 Live Biotherapeutic Products (LBPs)
6.6.3 Monoclonal Microbials
6.6.4 Engineered Bacteria
6.6.5 Modulatory Microbiome Therapeutics
6.6.6 Subtractive Microbiome Therapeutics
6.6.7 Global Market Outlook by Type (Pre-COVID-19 Analysis)
6.6.8 Global Market Outlook by Type (Post-COVID-19 Impact Recovery Analysis)
6.7 Global Market Outlook by Product (COVID-19 Impact Recovery Analysis)
7 North America Human Microbiome Therapeutics Market
7.1 North America Market Overview
7.2 North America Market Outlook by Value (COVID-19 Impact Recovery Analysis)
7.3 North America Market Outlook by Country (COVID-19 Impact Recovery Analysis)
7.4 US Market Outlook
7.4.1 US Market Outlook by Value (COVID-19 Impact Recovery Analysis)
7.5 Canada Market Outlook
7.5.1 Canada Market Outlook by Value (COVID-19 Impact Recovery Analysis)
7.6 North America Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
7.7 North America Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
7.8 North America Market Outlook by Type (COVID-19 Impact Recovery Analysis)
7.9 North America Market Outlook by Product (COVID-19 Impact Recovery Analysis)
8 Europe Human Microbiome Therapeutics Market
8.1 Europe Market Overview
8.2 Europe Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.3 Europe Market Outlook by Country (COVID-19 Impact Recovery Analysis)
8.4 Russia Market Outlook
8.4.1 Russia Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.5 Germany Market Outlook
8.5.1 Germany Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.6 UK Market Outlook
8.6.1 UK Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.7 France Market Outlook
8.7.1 France Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.8 Italy Market Outlook
8.8.1 Italy Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.9 Rest of Europe Market Outlook
8.9.1 Rest of Europe Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.10 Europe Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
8.11 Europe Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
8.12 Europe Market Outlook by Type (COVID-19 Impact Recovery Analysis)
8.13 Europe Market Outlook by Product (COVID-19 Impact Recovery Analysis)
9 Asia-Pacific Human Microbiome Therapeutics Market
9.1 Asia-Pacific Market Overview
9.2 Asia-Pacific Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.3 Asia-Pacific Market Outlook by Country (COVID-19 Impact Recovery Analysis)
9.4 Japan Market Outlook
9.4.1 Japan Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.5 China Market Outlook
9.5.1 China Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.6 India Market Outlook
9.6.1 India Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.7 South Korea Market Outlook
9.7.1 South Korea Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.8 Australia Market Outlook
9.8.1 Australia Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.9 Rest of APAC Market Outlook
9.9.1 Rest of APAC Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.10 Asia-Pacific Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
9.11 Asia-Pacific Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
9.12 Asia-Pacific Market Outlook by Type (COVID-19 Impact Recovery Analysis)
9.13 Asia-Pacific Market Outlook by Product (COVID-19 Impact Recovery Analysis)
10 LAMEA Human Microbiome Therapeutics Market
10.1 LAMEA Market Overview
10.2 LAMEA Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.3 LAMEA Market Outlook by Country (COVID-19 Impact Recovery Analysis)
10.4 Brazil Market Outlook
10.4.1 Brazil Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.5 Saudi Arabia Market Outlook
10.5.1 Saudi Arabia Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.6 South Africa Market Outlook
10.6.1 South Africa Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.7 Mexico Market Outlook
10.7.1 Mexico Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.8 UAE Market Outlook
10.8.1 UAE Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.9 Rest od LAMEA Market Outlook
10.9.1 Rest of LAMEA Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.10 LAMEA Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
10.11 LAMEA Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
10.12 LAMEA Market Outlook by Type (COVID-19 Impact Recovery Analysis)
10.13 LAMEA Market Outlook by Product (COVID-19 Impact Recovery Analysis)
11 Competitive Landscape Analysis
11.1 Investment in Microbiome Therapeutics
11.2 Public Funding Initiatives
11.3 Private Funding Initiatives
11.3.1 Seventure Partners
11.3.2 Flagship Pioneering
11.4 Collaborations and Partnerships in the Global Market
11.5 Licensing and Manufacturing Agreements
11.6 Mergers and Acquisitions in the Global Market
11.7 Leading Market Players in Microbiome Therapeutics Market
11.8 Leading Market Players in Additive Microbiome Therapeutics Market
11.9 Leading Market Players in Modulatory Microbiome Therapeutics Market
11.10 Leading Market Players in Subtractive Microbiome Therapeutics Market
12 Global Human Microbiome Patent Analysis
12.1 Patent Overview
12.2 Patent Analysis
12.3 Patents by Year
12.4 Patents by Type
12.5 Patents by Disease Type
12.6 Patents by Company
12.7 Patents by Country
12.8 Patents by Assignee
13 Global Human Microbiome Clinical Trial Analysis
13.1 Clinical Trial Analysis by Disease Category
13.2 Share of Clinical Trials
13.3 Clinical Trial Analysis by Treatment Strategy
13.4 Share of Clinical Trials
13.5 Clinical Trial Analysis by Company
13.6 Share of Clinical Trials
13.7 Microbiome Therapeutics in Discovery and Preclinical Development
13.8 Microbiome Therapeutics Clinical Trials in Phase 3
14 Leading Company Profiles
14.1 AbbVie Inc. Company
14.1.1 Company Information
14.1.2 Company Overview
14.1.3 Company Financial Profile
14.1.4 Company Product Offerings
14.1.5 Company Recent Developments
14.2 Bristol-Myers Squibb Company
14.2.1 Company Information
14.2.2 Company Overview
14.2.3 Company Financial Profile
14.2.4 Company Product Offerings
14.2.5 Company Recent Developments
14.3 Dow Inc. Chemical Company
14.3.1 Company Information
14.3.2 Company Overview
14.3.3 Company Financial Profile
14.3.4 Company Product Offerings
14.3.5 Company Recent Developments
14.4 Takeda Pharmaceuticals Company Ltd.
14.4.1 Company Information
14.4.2 Company Overview
14.4.3 Company Financial Profile
14.4.4 Company Product Offerings
14.4.5 Company Recent Developments
14.5 Johnson & Johnson Company
14.5.1 Company Information
14.5.2 Company Overview
14.5.3 Company Financial Profile
14.5.4 Company Product Offerings
14.5.5 Company Recent Developments
14.6 DuPont de Nemours, Inc Company
14.6.1 Company Information
14.6.2 Company Overview
14.6.3 Company Financial Profile
14.6.4 Company Product Offerings
14.6.5 Company Recent Developments
14.7 Merck & Co. Inc Company
14.7.1 Company Information
14.7.2 Company Overview
14.7.3 Company Financial Profile
14.7.4 Company Product Offerings
14.7.5 Company Recent Developments
14.8 Pfizer Inc. Company
14.8.1 Company Information
14.8.2 Company Overview
14.8.3 Company Financial Profile
14.8.4 Company Product Offerings
14.8.5 Company Recent Developments
14.9 Vertex Pharmaceuticals Company
14.9.1 Company Information
14.9.2 Company Overview
14.9.3 Company Financial Profile
14.9.4 Company Product Offerings
14.9.5 Company Recent Developments
14.10 Evelo Biosciences, Inc Company
14.10.1 Company Information
14.10.2 Company Overview
14.10.3 Company Financial Profile
14.10.4 Company Product Offerings
14.10.5 Company Recent Developments
14.11 Kaleido Biosciences Inc Company
14.11.1 Company Information
14.11.2 Company Overview
14.11.3 Company Financial Profile
14.11.4 Company Product Offerings
14.11.5 Company Recent Developments
14.12 Seres Therapeutics Inc Company
14.12.1 Company Information
14.12.2 Company Overview
14.12.3 Company Financial Profile
14.12.4 Company Product Offerings
14.12.5 Company Recent Developments
14.13 PureTech Health PLC Company
14.13.1 Company Information
14.13.2 Company Overview
14.13.3 Company Financial Profile
14.13.4 Company Product Offerings
14.13.5 Company Recent Developments
14.14 Nestle S.A. Company
14.14.1 Company Information
14.14.2 Company Overview
14.14.3 Company Financial Profile
14.14.4 Company Product Offerings
14.14.5 Company Recent Developments
14.15 Mayo Clinic Company
14.15.1 Company Information
14.15.2 Company Overview
14.15.3 Company Financial Profile
14.15.4 Company Product Offerings
14.15.5 Company Recent Developments
14.16 MaaT Pharma SA Company
14.16.1 Company Information
14.16.2 Company Overview
14.16.3 Company Financial Profile
14.16.4 Company Product Offerings
14.16.5 Company Recent Developments
14.17 4D Pharma Plc Company
14.17.1 Company Information
14.17.2 Company Overview
14.17.3 Company Financial Profile
14.17.4 Company Product Offerings
14.17.5 Company Recent Developments
14.18 Assembly Biosciences, Inc Company
14.18.1 Company Information
14.18.2 Company Overview
14.18.3 Company Financial Profile
14.18.4 Company Product Offerings
14.18.5 Company Recent Developments
14.19 F. Hoffmann-La Roche Ltd Company
14.19.1 Company Information
14.19.2 Company Overview
14.19.3 Company Financial Profile
14.19.4 Company Product Offerings
14.19.5 Company Recent Developments
14.20 Vedanta Biosciences Company
14.20.1 Company Information
14.20.2 Company Overview
14.20.3 Company Financial Profile
14.20.4 Company Product Offerings
14.20.5 Company Recent Developments
15 Conclusion & Recommendations
16 Glossary
List of Figures
Figure 1.1 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
Figure 3.1 Differences in Human Genome and Microbiome
Figure 3.2 Bacterial Distribution, by Body Site
Figure 3.3 Essential Functions of Human Microbiome
Figure 5.1 SWOT Analysis of Global Human Microbiome Therapeutics Market
Figure 6.1 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
Figure 6.2 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 6.3 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 6.4 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 6.5 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 6.6 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %)
Figure 6.7 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 6.8 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 6.9 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 6.10 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 6.11 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %)
Figure 6.12 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 6.13 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 6.14 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 6.15 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 6.16 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %)
Figure 6.17 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 6.18 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 6.19 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 6.20 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 6.21 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %)
Figure 6.22 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 6.23 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 6.24 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 6.25 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 6.26 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %)
Figure 6.27 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 6.28 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 6.29 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 6.30 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 7.1 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
Figure 7.2 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 7.3 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 7.4 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 7.5 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 7.6 North America Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %)
Figure 7.7 North America Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 7.8 North America Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 7.9 North America Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 7.10 North America Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 7.11 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %)
Figure 7.12 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 7.13 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 7.14 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 7.15 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 7.16 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %)
Figure 7.17 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 7.18 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 7.19 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 7.20 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 7.21 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %)
Figure 7.22 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 7.23 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 7.24 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 7.25 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 7.26 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %)
Figure 7.27 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 7.28 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 7.29 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 7.30 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 8.1 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
Figure 8.2 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 8.3 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 8.4 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 8.5 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 8.6 Europe Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %)
Figure 8.7 Europe Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 8.8 Europe Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 8.9 Europe Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 8.10 Europe Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 8.11 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %)
Figure 8.12 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 8.13 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 8.14 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 8.15 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 8.16 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %)
Figure 8.17 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 8.18 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 8.19 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 8.20 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 8.21 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %)
Figure 8.22 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 8.23 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 8.24 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 8.25 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 8.26 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %)
Figure 8.27 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 8.28 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 8.29 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 8.30 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 9.1 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
Figure 9.2 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 9.3 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 9.4 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 9.5 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 9.6 Asia-Pacific Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %)
Figure 9.7 Asia-Pacific Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 9.8 Asia-Pacific Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 9.9 Asia-Pacific Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 9.10 Asia-Pacific Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 9.11 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %)
Figure 9.12 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 9.13 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 9.14 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 9.15 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 9.16 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %)
Figure 9.17 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 9.18 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 9.19 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 9.20 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 9.21 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %)
Figure 9.22 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 9.23 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 9.24 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 9.25 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 9.26 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %)
Figure 9.27 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 9.28 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 9.29 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 9.30 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 10.1 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
Figure 10.2 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 10.3 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 10.4 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 10.5 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 10.6 LAMEA Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %)
Figure 10.7 LAMEA Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 10.8 LAMEA Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 10.9 LAMEA Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 10.10 LAMEA Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 10.11 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %)
Figure 10.12 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 10.13 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 10.14 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 10.15 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 10.16 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %)
Figure 10.17 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 10.18 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 10.19 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 10.20 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 10.21 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %)
Figure 10.22 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 10.23 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 10.24 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 10.25 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 10.26 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %)
Figure 10.27 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
Figure 10.28 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
Figure 10.29 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
Figure 10.30 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
Figure 14.1 AbbVie Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.2 AbbVie Inc: Company Operating Income 2015-2019 (US$Mn)
Figure 14.3 AbbVie Inc: Company EBITDA 2015-2019 (US$Mn)
Figure 14.4 AbbVie Inc: Company Net Income/Loss 2015-2019 (US$Mn)
Figure 14.5 Bristol-Myers Squibb: Company Revenue 2015-2019 (US $Mn, AGR %)
Figure 14.6 Bristol-Myers Squibb: Company Operating Income 2015-2019 (US $Mn)
Figure 14.7 Bristol-Myers Squibb: Company EBITDA 2015-2019 (US $Mn)
Figure 14.8 Bristol-Myers Squibb: Company Net Income/Loss 2015-2019 (US $Mn)
Figure 14.9 Dow Inc Chemical: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.10 Dow Inc Chemical: Company Operating Income 2015-2019 (US$Mn)
Figure 14.11 Dow Inc Chemical: Company EBITDA 2015-2019 (US$Mn)
Figure 14.12 Dow Inc Chemical: Company Net Income/Loss 2015-2019 (US$Mn)
Figure 14.13 Takeda Pharmaceuticals: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.14 Takeda Pharmaceuticals: Company Operating Income 2015-2019 (US$Mn)
Figure 14.15 Takeda Pharmaceuticals: Company EBITDA 2015-2019 (US$Mn)
Figure 14.16 Takeda Pharmaceuticals: Company Net Income/Loss 2015-2019 (US$Mn)
Figure 14.17 Johnson & Johnson: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.18 Johnson & Johnson: Company Operating Income 2015-2019 (US$Mn)
Figure 14.19 Johnson & Johnson: Company EBITDA 2015-2019 (US$Mn)
Figure 14.20 Johnson & Johnson: Company Net Income/Loss 2015-2019 (US$Mn)
Figure 14.21 KKK: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.22 KKK: Company Operating Income 2015-2019 (US$Mn)
Figure 14.23 KKK: Company EBITDA 2015-2019 (US$Mn)
Figure 14.24 KKK: Company Net Income/Loss 2015-2019 (US$Mn)
Figure 14.25 Merck & Co. Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.26 Merck & Co. Inc: Company Operating Income 2015-2019 (US$Mn)
Figure 14.27 Merck & Co. Inc: Company EBITDA 2015-2019 (US$Mn)
Figure 14.28 Merck & Co. Inc: Company Net Income/Loss 2015-2019 (US$Mn)
Figure 14.29 Pfizer Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.30 Pfizer Inc: Company Operating Income 2015-2019 (US$Mn)
Figure 14.31 Pfizer Inc: Company EBITDA 2015-2019 (US$Mn)
Figure 14.32 Pfizer Inc: Company Net Income/Loss 2015-2019 (US$Mn)
Figure 14.33 Vertex Pharmaceuticals: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.34 Vertex Pharmaceuticals: Company Operating Income 2015-2019 (US$Mn)
Figure 14.35 Vertex Pharmaceuticals: Company EBITDA 2015-2019 (US$Mn)
Figure 14.36 Vertex Pharmaceuticals: Company Net Income/Loss 2015-2019 (US$Mn)
Figure 14.37 Evelo Biosciences, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.38 Evelo Biosciences, Inc: Company Operating Income 2015-2019 (US$Mn)
Figure 14.39 Evelo Biosciences, Inc: Company EBITDA 2015-2019 (US$Mn)
Figure 14.40 Evelo Biosciences, Inc: Company Net Income/Loss 2015-2019 (US$Mn)
Figure 14.41 Kaleido Biosciences, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.42 Kaleido Biosciences, Inc: Company Operating Income 2015-2019 (US$Mn)
Figure 14.43 Kaleido Biosciences, Inc: Company EBITDA 2015-2019 (US$Mn)
Figure 14.44 Kaleido Biosciences, Inc: Company Net Income/Loss 2015-2019 (US$Mn)
Figure 14.45 Seres Therapeutics, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.46 Seres Therapeutics, Inc: Company Operating Income 2015-2019 (US$Mn)
Figure 14.47 Seres Therapeutics, Inc: Company EBITDA 2015-2019 (US$Mn)
Figure 14.48 Seres Therapeutics, Inc: Company Net Income/Loss 2015-2019 (US$Mn)
Figure 14.49 PureTech Health Plc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.50 PureTech Health Plc: Company Operating Income 2015-2019 (US$Mn)
Figure 14.51 PureTech Health Plc: Company EBITDA 2015-2019 (US$Mn)
Figure 14.52 PureTech Health Plc: Company Net Income/Loss 2015-2019 (US$Mn)
Figure 14.53 Nestle S.A.: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.54 Nestle S.A.: Company Operating Income 2015-2019 (US$Mn)
Figure 14.55 Nestle S.A.: Company EBITDA 2015-2019 (US$Mn)
Figure 14.56 Nestle S.A.: Company Net Income/Loss 2015-2019 (US$Mn)
Figure 14.57 4D Pharma Plc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.58 4D Pharma Plc: Company Operating Income 2015-2019 (US$Mn)
Figure 14.59 4D Pharma Plc: Company EBITDA 2015-2019 (US$Mn)
Figure 14.60 4D Pharma Plc: Company Net Income/Loss 2015-2019 (US$Mn)
Figure 14.61 Assembly Biosciences, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.62 Assembly Biosciences, Inc: Company Operating Income 2015-2019 (US$Mn)
Figure 14.63 Assembly Biosciences, Inc: Company EBITDA 2015-2019 (US$Mn)
Figure 14.64 Assembly Biosciences, Inc: Company Net Income/Loss 2015-2019 (US$Mn)
Figure 14.65 F. Hoffmann-La Roche Ltd: Company Revenue 2015-2019 (US $Mn, AGR %)
Figure 14.66 F. Hoffmann-La Roche Ltd: Company Operating Income 2015-2019 (US $Mn)
Figure 14.67 F. Hoffmann-La Roche Ltd: Company EBITDA 2015-2019 (US $Mn)
Figure 14.68 F. Hoffmann-La Roche Ltd: Company Net Income/Loss 2015-2019 (US $Mn)
List of Tables
Table 1.1 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 2.1 Global Human Microbiome Therapeutics Market Summary Table
Table 3.1 Technologies for Microbiome Research
Table 3.2 Dysbiosis in Microbiome
Table 6.1 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 6.2 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 6.3 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 6.4 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 6.5 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 6.6 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 6.7 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 6.8 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 6.9 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 6.10 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 6.11 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 6.12 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 6.13 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 6.14 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 6.15 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 6.16 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 6.17 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 6.18 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 6.19 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 6.20 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 6.21 Modulatory Microbiome Therapeutics
Table 6.22 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 6.23 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 6.24 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 6.25 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 6.26 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 6.27 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 6.28 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 6.29 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 6.30 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 6.31 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 7.1 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 7.2 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 7.3 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 7.4 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 7.5 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 7.6 US Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 7.7 US Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 7.8 US Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 7.9 US Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 7.10 US Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 7.11 Canada Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 7.12 Canada Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 7.13 Canada Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 7.14 Canada Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 7.15 Canada Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 7.16 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 7.17 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 7.18 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 7.19 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 7.20 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 7.21 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 7.22 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 7.23 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 7.24 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 7.25 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 7.26 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 7.27 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 7.28 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 7.29 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 7.30 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 7.31 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 7.32 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 7.33 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 7.34 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 7.35 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 8.1 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 8.2 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 8.3 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 8.4 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 8.5 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 8.6 Russia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 8.7 Russia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 8.8 Russia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 8.9 Russia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 8.10 Russia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 8.11 Germany Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 8.12 Germany Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 8.13 Germany Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 8.14 Germany Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 8.15 Germany Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 8.16 UK Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 8.17 UK Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 8.18 UK Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 8.19 UK Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 8.20 UK Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 8.21 France Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 8.22 France Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 8.23 France Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 8.24 France Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 8.25 France Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 8.26 Italy Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 8.27 Italy Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 8.28 Italy Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 8.29 Italy Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 8.30 Italy Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 8.31 Rest of Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 8.32 Rest of Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 8.33 Rest of Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 8.34 Rest of Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 8.35 Rest of Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 8.36 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 8.37 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 8.38 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 8.39 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 8.40 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 8.41 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 8.42 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 8.43 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 8.44 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 8.45 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 8.46 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 8.47 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 8.48 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 8.49 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 8.50 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 8.51 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 8.52 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 8.53 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 8.54 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 8.55 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 9.1 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 9.2 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 9.3 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 9.4 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 9.5 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 9.6 Japan Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 9.7 Japan Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 9.8 Japan Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 9.9 Japan Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 9.10 Japan Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 9.11 China Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 9.12 China Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 9.13 China Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 9.14 China Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 9.15 China Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 9.16 India Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 9.17 India Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 9.18 India Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 9.19 India Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 9.20 India Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 9.21 South Korea Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 9.22 South Korea Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 9.23 South Korea Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 9.24 South Korea Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 9.25 South Korea Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 9.26 Australia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 9.27 Australia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 9.28 Australia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 9.29 Australia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 9.30 Australia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 9.31 Rest of Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 9.32 Rest of Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 9.33 Rest of Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 9.34 Rest of Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 9.35 Rest of Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 9.36 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 9.37 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 9.38 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 9.39 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 9.40 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 9.41 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 9.42 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 9.43 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 9.44 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 9.45 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 9.46 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 9.47 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 9.48 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 9.49 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 9.50 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 9.51 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 9.52 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 9.53 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 9.54 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 9.55 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 10.1 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 10.2 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 10.3 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 10.4 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 10.5 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 10.6 Brazil Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 10.7 Brazil Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 10.8 Brazil Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 10.9 Brazil Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 10.10 Brazil Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 10.11 Saudi Arabia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 10.12 Saudi Arabia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 10.13 Saudi Arabia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 10.14 Saudi Arabia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 10.15 Saudi Arabia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 10.16 South Africa Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 10.17 South Africa Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 10.18 South Africa Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 10.19 South Africa Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 10.20 South Africa Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 10.21 Mexico Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 10.22 Mexico Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 10.23 Mexico Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 10.24 Mexico Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 10.25 Mexico Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 10.26 UAE Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 10.27 UAE Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 10.28 UAE Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 10.29 UAE Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 10.30 UAE Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 10.31 Rest of LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 10.32 Rest of LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 10.33 Rest of LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 10.34 Rest of LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 10.35 Rest of LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 10.36 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 10.37 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 10.38 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 10.39 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 10.40 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 10.41 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 10.42 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 10.43 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 10.44 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 10.45 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 10.46 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 10.47 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 10.48 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 10.49 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 10.50 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 10.51 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %)
Table 10.52 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
Table 10.53 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
Table 10.54 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
Table 10.55 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
Table 11.1 Historical Funding Activity in Microbiome Therapeutics, 2015 and 2016
Table 11.2 Public Funding in Microbiome Therapeutics, 2018-August 2020
Table 11.3 Venture Funding in Microbiome Therapeutics, 2017-August 2020
Table 11.4 Collaborations and Partnerships in the Microbiome Therapeutics Market, 2017-August 2020
Table 11.5 Licensing and Manufacturing Agreements in the Microbiome Therapeutics Market, 2017-August 2020
Table 11.6 Leading Developers of Additive Microbiome Therapeutics, 2019
Table 11.7 Leading Developers of Modulatory Microbiome Therapeutics, 2019
Table 11.8 Leading Developers of Subtractive Microbiome Therapeutics, 2019
Table 12.1 Patents Issued for Microbiome Therapeutics, by Year, 2017-August 2020 (Number)
Table 12.2 Patents Issued for Microbiome Therapeutics, by Type, 2017- August 2020 (Number/%)
Table 12.3 Patents Issued for Microbiome Therapeutics, by Disease Type, 2017-August 2020 (Number/%)
Table 12.4 Patents Issued for Microbiome Therapeutics, by Company, 2017-August 2020 (Number)
Table 12.5 Patents Issued for Microbiome Therapeutics, by Country, 2017-August 2020 (Number/%)
Table 12.6 Patents Issued for Microbiome Therapeutics, by Assignee, 2017-August 2020 (Number/%)
Table 13.1 Clinical Trials in Microbiome Therapeutics, by Disease Type, August 2020 (Number)
Table 13.2 Share of Clinical Trials in Microbiome Therapeutics, by Disease Type, August 2020 (%)
Table 13.3 Clinical Trials in Microbiome Therapeutics, by Treatment Strategy
Table 13.4 Share of Clinical Trials in Microbiome Therapeutics, by Treatment Strategy (%)
Table 13.5 Clinical Trials in Microbiome Therapeutics, by Company
Table 13.6 Share of Clinical Trials in Microbiome Therapeutics, by Top 10 Companies (%)
Table 13.7 Microbiome Therapeutics in Discovery and Preclinical Development
Table 13.8 Microbiome Therapeutics Clinical Trials in Phase 3
Table 14.1 AbbVie Inc: Company Information
Table 14.2 AbbVie Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.3 AbbVie Inc: Company Product and Service Offerings
Table 14.4 AbbVie Inc: Company Product Pipeline
Table 14.5 AbbVie Inc: Company Recent Developments till Sept,2020
Table 14.6 Bristol-Myers Squibb: Company Information
Table 14.7 Bristol-Myers Squibb: Company Revenue 2015-2019 (US $Mn, AGR %)
Table 14.8 Bristol-Myers Squibb: Company Product and Service Offerings
Table 14.9 Bristol-Myers Squibb: Company Product Pipeline
Table 14.17 Takeda Pharmaceuticals: Company Product and Service Offerings
List of Companies Profiled
4D pharma plc (4D)
AbbVie Inc. (AbbVie)
Assembly Biosciences, Inc
Bristol-Myers Squibb
Dow Inc Chemical
DuPont de Nemours, Inc.
Evelo Biosciences, Inc.
F. Hoffmann-La Roche Ltd
Johnson & Johnson
Kaleido Biosciences, Inc.
MaaT Pharma SA
Mayo Clinic
Merck & Co. Inc
Nestle S.A.
Pfizer Inc.
PureTech Health PLC
Seres Therapeutics, Inc.
Takeda Pharmaceutical Company Limited
Vedanta Biosciences
Vertex Pharmaceuticals
List of Other Companies
Accinov
ActoGeniX
Aju IB Investment
Ally Bridge Group
Amrita Therapeutics
AOBiome, LLC
AquaBounty Technologies
Arctic Aurora Life Science
Assembly Biosciences
Azitra
BaseClear
Bio-Technology General
BIOASTER
Biological & Popular Culture, Inc.
BiomX
Bioverativ Therapeutics
Blue Turtle Bio
Bristol-Myers Squibb
BYTC Corp
C3J Therapeutics
Caelus Health
Cd4 Biosciences, Inc.
Cedars-Sinai Medical Centre
Chengdu Sen Nuo Wei Biotechnology Co., Ltd
CLI Ventures
Codexis Laboratories Hungary Kft
CoreBiome
Crestovo
CRS Bio, Inc
DayTwo
Effective Pharmaceuticals, Inc.
Enterome Bioscience
Enterome SA
EnviroFlight, LLC
Epibiome
Epitope Pharmaceuticals, Inc.
Evelo Biosciences
Evolve BioSystems
Ferring Pharmaceuticals
Ferring Sas
Finch Therapeutics
Finch Therapeutics Group, Inc.
Genomatix Ltd.
Genten Therapeutics, Inc.
GenVec, Inc.
Global Bioscience Company
GT Biologics Limited
Hartlab LLC
Harvest Capital Strategies, LLC
HealthMine, Inc
IBBL
iCarbonX
Igen Biotech Group
ImmuneBiotech AB
Immuron, Ltd.
INC Research
Intrexon Actobiotics N.V.
Intrexon Energy Partners II, LLC
Janssen Biotech
Kallyope
Leading Biosciences
LNC Therapeutics
Lundbeckfond Ventures
MaaT Pharma SA
MatriSys Bioscience
Microbiome Therapeutics, LLC
Microbiomics Limited
Mirna Therapeutics
Nitrocell
NIZO
Nubiyota
NuMe Health LLC
Okanagan Specialty Fruits Inc.
Omnes Capital
OpenBiome
OptiBiotix Health plc
OrbiMed HealthCare Fund Management
Osel, Inc.
OvaXon, LLC
Oxitec
Symbiotix Biotherapies
Synlogic, Inc.
Synthetic Biologics, Inc.
Synthetic Genomics, Inc.
TargEDys
Tech Coast Angels (TCA)
The Microbiota Company Limited
Trans Ova Genetics LC
Tucana Health Limited
Vedanta Biosciences Inc.
Veristat
Vertex Pharmaceuticals Inc.
Whole Biome
Xycrobe Therapeutics
List of Organizations Mentioned in the Report
Alimentary Pharmabiotic Centre
APC Microbiome Institute
Central Drugs Standard Control Organisation (CDSCO)
French National Institute for Agricultural Research
Hadasit Medical Research Services & Development Ltd
Hadassah Medical Center
Health Canada
Institut National de la Recherche Agronomique
John Theurer Cancer Center of Hackensack Meridian Health
King’s College London
La Trobe University
Lawrence Berkeley National Laboratory
Leiden University Medical Center
Mayo clinic
Medical University of Graz
Medicines and Healthcare products Regulatory Agency (MHRA)
Medicines Control Council (MCC)
Memorial Sloan Kettering Cancer Center
Microbiome Institute at University College Cork
Ministry of Health, Labour and Welfare (MHLW)
Monash University
Murdoch Children Research Institute
National Institute of Allergy and Infectious Diseases
NYU Langone Health
Orange Country Research Center
Pan American Health Organization (PAHO)
Roswell Park Comprehensive Cancer Center
Ruprecht-Karls-University Heidelberg
Saudi Food and Drug Authority (SFDA)
St. Joseph’s Hamilton
Stanford Cancer Institute
The Endocrine Society
The Parker Institute for Cancer Immunotherapy
Therapeutic Goods Administration (TGA)
University of British Columbia
University of California
University of Melbourne
University of Minnesota
University of Nebraska
University of Pennsylvania
University of South Alabama (USA) Mitchell Cancer Institut
University of Texas at Austin
University of Texas MD Anderson Cancer Center
University of Tokyo
USA Mitchell Cancer Center
World Health Organization (WHO)
World Intellectual Property Organization WIPO
World Trade Organization (WTO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
